Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
J Infect Dis
; 205(9): 1456-63, 2012 May 01.
Article
em En
| MEDLINE
| ID: mdl-22457289
ABSTRACT
Malaria continues to be a major public health concern, and there are concerted efforts to eliminate it. The quest for a vaccine remains a top priority, and vaccines based on the circumsporozoite protein (CSP) are among the lead candidates, with the RTS,S vaccine currently undergoing phase 3 testing in Africa. Previous studies have reported anti-CSP antibody-mediated enhancement of in vitro invasion of homologous sporozoites. This effect has been shown to be concentration dependent; high-level antibodies are inhibitory, whereas low-level antibodies lead to enhancement of invasion. Nondominant shared epitopes may lead to the generation of low titers of cross-reactive antibodies that may prove to be detrimental. We report cross-species recognition of Plasmodium falciparum and Plasmodium berghei sporozoites by anti-Plasmodium vivax CSP serum samples. In addition, we report that vaccination of mice with VMP001, a P. vivax CSP vaccine candidate, reduces, not enhances, P. berghei infection in mice.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas de Protozoários
/
Vacinas Antimaláricas
/
Proteção Cruzada
/
Malária
Limite:
Animals
País/Região como assunto:
Africa
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article